08:00 , Jan 15, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: P. falciparum P-type cation-transporter ATPase 4 (PfATP4)

Infectious disease INDICATION: Malaria Mouse and in vitro studies have identified a new ATPase inhibitor that could help treat malaria infections. Whole genome sequencing of mutant strains of the P. falciparum parasite resistant to the compound identified...
08:00 , Dec 19, 2013 |  BC Innovations  |  Targets & Mechanisms

Lipid kinase enters the malaria stage

A Novartis AG-University of California, San Diego-led consortium has identified a new class of antimalarials that, unlike marketed drugs, eliminates Plasmodium at all stages of its infection cycle.1 The pharma is developing derivatives of the...
07:00 , Oct 10, 2011 |  BC Week In Review  |  Clinical News

Sevuparin/DF02: Phase I/II started

Dilaforette began an open-label, dose-escalation, Thai Phase I/II trial to compare Malanil atovaquone/proguanil plus IV Sevuparin/DF02 vs. Malanil alone in about 98 patients with uncomplicated falciparum malaria. GlaxoSmithKline plc (LSE:GSK; NYSE:GSK, London, U.K.) markets...
08:00 , Nov 6, 2008 |  BC Innovations  |  Distillery Techniques

Technology: Drug platforms

This week in techniques Approach Summary Licensing status Publication and contact nformation Drug platforms Genome of Plasmodium...
07:00 , Aug 14, 2008 |  BC Innovations  |  Distillery Techniques

This Week in Techniques

This week in techniques Approach Summary Licensing status Publication and contact information Viral vector vaccines for high-titer antibody induction ...
07:00 , Jul 24, 2000 |  BC Week In Review  |  Clinical News

Malarone atovaquone/proguanil regulatory update

The FDA granted marketing approval for Malarone, an oral fixed dosage combination of two previously approved antimalarial drugs, to prevent and treat malaria in children and adults. Glaxo Wellcome plc (LSE:GLXO; GLX), London, U.K.   Product:...